Individuals carrying a specific polymorphism of SLC19A1 have lower levels of folate. Other studies have also shown that individuals carrying the c.80AA polymorphism who are treated with methotrexate have higher levels of this anti-folate chemotherapeuticagent. Personalized dosing of the drug depending on the patient's genotype may therefore be required.